New personal view: Urgent considerations for booster vaccination strategies against Ebola virus disease

thelancet.com/journals/lanin…

New personal view: Evaluation of a single-dose HPV vaccine strategy for promoting vaccine, health, and gender equity

thelancet.com/journals/lanin…

The first real world longitudinal population-based data on the use of nirsevimab as universal prophylaxis against respiratory syncytial virus #RSV - the #NIRSEGAL study (nirsegal.es/en) of Galicia- has been just published at The Lancet Infectious Diseases authors.elsevier.com/a/1j0Of5E-UogW…👇1/X

El primer estudio de base poblacional en mundo real de efectividad del uso de nirsevimab como profilaxis universal frente a VRS en Galicia (estudio #NIRSEGAL nirsegal.es) se acaba de publicar en The Lancet Infectious Diseases Articulo completo aqui: authors.elsevier.com/a/1j0Of5E-UogW… 👇1/X

How is AI transforming the landscape of research and publishing, and how does it contribute to misinformation?

Join us April 29 @ 830 am in Room B at #ECCMID #ESCMIDGlobal2024

Hear from Ursula Hofer, EIC of The Lancet Infectious Diseases, NIH's David Resnik, and me!

The Lancet Infectious Diseases ha volgut homenatjar els investigadors catalans:

-El Quique Bassat per la recerca en infeccions infantils a ISGlobal
-La Nuria Izquierdo per les troballes en VIH a l'IrsiCaixa
-Jo mateix per la feina en infeccions epidèmiques tropicals a la Fundació Lluita contra les Infeccions

Join editors from The Lancet Microbe & The Lancet Infectious Diseases for our #ESCMIDGlobal session, exploring the latest content from The Lancet Group on emerging infections

Sign up for Lancet Conference Alerts and be notified of content presented at events in your field: hubs.li/Q02tLPLG0